Castuner

Słuchaj w swojej aplikacji

Odcinki

395 odcinków

  1. Personalized Treatment Strategies for Hyperkalemia: Bridging Evidence and Clinical Practice Needs 5:30
  2. Hyperkalemia as a Barrier to GDMT: Why “Stopping GDMT” Is Often the Wrong Reflex 8:45
  3. Differentiating Oral Potassium Binders: Mechanism, Onset, and Sodium Load 8:45
  4. The Edema Question: Selecting a Potassium Binder in Patients With HF or Congestion 5:45
  5. Potassium Binders to Optimize GDMT Therapy in HFrEF 6:45
  6. CKD, Diabetes, and Albuminuria: Keeping Kidney-Protective Therapy on Board Despite Hyperkalemia 9:00
  7. From Lab Alert to Action Plan: Monitoring Potassium Without Undermining Cardiorenal Protection 5:15
  8. The Binder Selection Playbook: Matching the Right Strategy to the Right Patient 17:15
  9. The Hidden Danger of IgAN: Pathogenesis and Unmet Needs 6:00
  10. Unmasking IgAN: Achieving Earlier Diagnosis 6:45
  11. Proteinuria in IgAN: The Signal, The Target, and the Treatment Goal 6:30
  12. Navigating KDIGO Guidance in IgAN 4:15
  13. Mechanisms Matter! Optimizing Proteinuria Reduction In IgAN 4:30
  14. Translating Evidence into IgAN Care 8:45
  15. The Evolving Role of Biomarkers in IgAN 4:45
  16. The Future of IgAN Care 5:30
  17. Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders 5:15
  18. Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression 6:00
  19. The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape 7:30
  20. Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens 3:45
  21. Engaging Patients With Heart Failure and Chronic Hyperkalemia: Shared Decision-Making to Support Guideline-Directed Medical Therapy 9:00
  22. A New Lens on DKA: Leveraging the Latest Tech for Improved Patient Outcomes 16:45
  23. Patient Portal: Leveraging Technology to Improve Safety with Clinical Decision-Making for People with Diabetes 15:00
  24. CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs 36:45
  25. Treating Outside the Box: New Pathways to Retinal Vascular Stability 44:00
  26. Addressing the Burden of PH-ILD: Early Recognition, Evidence-Based Management, and Care Coordination 47:15
  27. Ready, Set, Act! Opportunities to Address Persistent Unmet Needs in Patients With HFrEF: A Case-Based Discussion 16:00
  28. Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma 5:30
  29. Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients 9:15
  30. Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma 5:15
  31. Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients 9:45
  32. Hypoparathyroidism – The Critical Role of Genetics in Your Differential Diagnosis 45:00
  33. Mineralocorticoid Receptor Antagonists in Heart Failure: The Evolving Treatment Landscape 55:00
  34. Overcoming Challenges in Transthyretin Cardiac Amyloidosis 58:45
  35. Frontline Champions: Nurses as Drivers of Symptom-Based CKD-aP Care 7:30
  36. CKD-aP Uncovered Prevalence & Pathophysiology 5:15
  37. When Itching Hurts: Quality of Life Disruption in CKD-aP 5:30
  38. Gabapentinoids: Safety Considerations and Downstream Outcomes 4:15
  39. From Scratch to Strategy: Talking About CKD-aP in Clinical Practice 5:00
  40. Spotlight on Assessment: Tools That Capture CKD-aP 7:30
  41. Reading Between the Lines: What PROMs Reveal About Itch 3:45
  42. What You Don’t See: A Patient’s View of Living with CKD-aP 6:00
  43. Winning the CKD-aP Battle: A United Physician-Nurse Front 5:00
  44. Conference Coverage at ICCBH 2026: From Achondroplasia Presentation to Practice 16:30
  45. Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice 32:30
  46. Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer 11:30
  47. Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer 9:30
  48. Case Consult: Treatment Strategies for FRα-Positive Platinum-Resistant Ovarian Cancer 9:30
  49. Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer 10:30
  50. Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer 10:00